| Name | Title | Contact Details |
|---|---|---|
Ibro Bektic |
Director Of Information Technology | Profile |
Headquartered in Lakewood, Colorado, Terumo Blood and Cell Technologies is a global leader in blood component, therapeutic apheresis and cellular technologies serving customers in more than 130 countries. As the only company with the unique combination of apheresis collections, manual and automated whole blood processing and pathogen reduction, we believe in the potential of blood to do even more for patients than it does today. This belief unites our organization, inspires our innovation and strengthens our collaboration with customers. Originally established in 1964 as COBE Laboratories, today, nearly 7,000 associates around the world are deeply committed to our vision of working together for better lives and our promise to unlock the potential of blood and cells. One way we back these words is through our pledge to be a conscientious corporate citizen and conduct our business in a way that provides social, environmental and economic benefit. At Terumo Blood and Cell Technologies, discovery never stops. We share a passion for thinking in new and different ways and we are proud to support education and research through a variety of community involvement activities as well as by providing grants to advance treatment options for patients. We know the work we do matters and has the potential to fundamentally improve health care. We remain dedicated to ensuring the lifesaving gift of blood is available around the world and to meeting and exceeding the needs of our customers and the patients we ultimately serve.
ApoCell is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PharmSource Information Services is a Springfield, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ontario Genomics Institute is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Plexium is the premier, next-generation Targeted Protein Degradation (TPD) company seeking to discover a wide range of monovalent target protein degraders that address the limitations of heterobifunctional degraders and cereblon IMiDs. The company is powered by its proprietary drug discovery platform designed to identify novel small molecules that induce selective degradation of drug target proteins through E3 ligase mediated proteasomal degradation. From molecular glues to monovalent degraders, Plexium is advancing a pipeline of novel targeted protein degraders for the treatment of cancer, neurodegeneration, and other diseases. Due to its expertise in TPD, Plexium has entered into strategic collaborations with Amgen and AbbVie to discover and develop a wide range of new therapies from cancer to neurological diseases. Supported by high quality investors, Plexium is well positioned to transform medicine.